Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2600116003) titled 'Efficacy and safety of Xuezhikang Capsules in population at intermediate risk of atherosclerotic cardiovascular disease' on Jan. 4.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The Second Affiliated Hospital of Harbin Medical University
Condition:
Intermediate risk atherosclerotic cardiovascular disease population
Intervention:
Treatment Group (Xuezhikang Capsules Group):Xuezhikang Capsules treatment
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-15
Target Sample Size: Treatment Group (Xuezhikang Capsules Group):250;Control Group (Placebo ...